Novel Blood-Based Assay Reveals Key Signals of Immunotherapy Response and Resistance in Sarcoma
Novel Blood Test Reveals Key Tumor Microenvironment Signals Predictive of Immunotherapy Outcomes in Sarcoma Aqtual, Inc., a precision medicine company focused on developing advanced cell-free DNA (cfDNA) diagnostics for oncology…
Qurient Doses First Patient in Phase 2 Trial of CDK7 Inhibitor Mocaciclib for HR-Positive Breast Cancer
Qurient Doses First Patient in Phase 2 Trial of Mocaciclib for CDK4/6 Inhibitor-Resistant HR-Positive Breast Cancer Qurient Co., Ltd. has announced a major clinical development milestone with the dosing of…
Sumitomo Pharma America Unveils First Clinical Findings for Investigational CHK1 Inhibitor SMP-3124LP at ASCO 2026
Sumitomo Pharma America Reports Promising Early Clinical Results for Investigational CHK1 Inhibitor SMP-3124LP in Advanced Solid Tumors Sumitomo Pharma America, Inc. (SMPA) has unveiled encouraging clinical findings from its ongoing…
Vertex Secures FDA Acceptance of BLA for Povetacicept in IgA Nephropathy
Vertex’s Biologics License Application for Povetacicept Accepted by FDA, Advancing Potential New Treatment for IgA Nephropathy Vertex Pharmaceuticals has reached an important regulatory milestone in its efforts to expand into…
Teleflex Launches $500 Million Private Offering of Senior Notes Due 2032
Teleflex Launches $500 Million Senior Notes Offering to Support Debt Refinancing Strategy Teleflex Incorporated has announced the launch of a private offering of $500 million in aggregate principal amount of…
FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA + XTANDI in HRR-Mutated mCRPC
FDA Approves FoundationOne CDx Tests as Companion Diagnostics for TALZENNA and XTANDI in HRR Gene–Mutated Metastatic Castration-Resistant Prostate Cancer Foundation Medicine, a global precision medicine company dedicated to advancing personalized…
Lysoway Therapeutics Secures Michael J. Fox Foundation Grant to Advance Parkinson’s Disease Therapy
Lysoway Therapeutics Secures Additional MJFF Funding to Advance TMEM175 Agonist Program for Parkinson’s Disease Lysoway Therapeutics, a biopharmaceutical company focused on developing small-molecule therapies that target lysosomal ion channels, has…
Corcept Therapeutics Shows Lifyorli Overall Survival Benefit in Platinum-Resistant Ovarian Cancer at ASCO 2026
Corcept Therapeutics Reports Statistically Significant Overall Survival Benefit for Lifyorli in Platinum-Resistant Ovarian Cancer at ASCO 2026 Corcept Therapeutics Incorporated, a commercial-stage biopharmaceutical company focused on discovering and developing therapies…
Veracyte OPTIMA Trial Shows Prosigna Identifies Breast Cancer Patients Who Can Avoid Chemotherapy
Veracyte’s Prosigna Test Shows Practice-Changing Results in Early Breast Cancer at ASCO 2026 OPTIMA Trial Veracyte, Inc., a leading cancer diagnostics company, has announced highly significant results from the independent…
Virion Therapeutics Reports Durable HBV Functional Cure Signals with HBsAg Decline at EASL 2026
Virion Therapeutics Reports Durable Functional Cure Signals in Chronic Hepatitis B with Single-Dose VRON-0200 at EASL 2026 Virion Therapeutics, LLC, a clinical-stage biotechnology company focused on developing next-generation T cell–based…
Beren Therapeutics Announces Six Presentations at 2026 APMRF Conference
Beren Therapeutics to Present Comprehensive Adrabetadex Data at 2026 NPC Research Conference, Highlighting Early Treatment Benefits and Mechanistic Insights Beren Therapeutics P.B.C., the parent company of Mandos LLC and a…
Bristol Myers Squibb Mezigdomide Cuts Myeloma Progression Risk by Over 50%
Bristol Myers Squibb’s Mezigdomide Combo Shows Strong Phase 3 Success in Relapsed Multiple Myeloma at ASCO 2026 Bristol Myers Squibb has announced encouraging late-breaking results from the Phase 3 SUCCESSOR-2…